Chronic Inflammatory Demyelinating PolyneuropathyPhase 2NCT02967679
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
A Phase 2 study testing MD1003 in people with Chronic Inflammatory Demyelinating Polyneuropathy and Peripheral Neuropathy, run by MedDay Pharmaceuticals SA at 1 site in France.
Trial summary
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects. Read more about this study
- Who is it for?
- Ages 20 to 85 years
- Conditions the study is for
- Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease
- What is being tested?
- MD1003
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteFrance
- Study dates
- 5 Dec 2016to 18 Mar 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female aged between 20 and 85 years.
- Patients fulfilling one of the following diagnosis:
- Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
- Five patients with proven genetic diagnosis of CMT1a or CMT1b
- Five patients with anti-MAG polyneuropathy.
- Electrophysiological parameters worsening for the past 3 years
Show all 11Show fewer
- Available EMG record, performed during the past 6 months to assess variability of NCV parameters
- Signed and dated written informed consent to participate in the study in accordance with local regulations
- Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
- In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study.
- Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination.
Who cannot join
- Any general chronic handicapping disease other than peripheral neuropathy
- Impossibility to perform the 10 meters walking test
- Impossibility to assess electrophysiological parameters
- Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer,
- Patients with hypersensitivity to MD1003 excipients (lactose)
- Laboratory tests out of normal range according to the reference laboratory values. Deviations may be accepted if considered by the investigator as not clinically significant with regards to the study continuation,
Show all 11Show fewer
- Patients with history or presence of alcohol abuse or drug addiction,
- Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve.
- Any new medication for neuropathy initiated less than 3 months prior to inclusion. For CIDP patients, relapse in the past 3 months before inclusion.
- Not easily contactable by the investigator in case of emergency or not capable to call the investigator
- Subjects without effective contraception
Trial locations and contacts
1 site in 1 country.
About this study
Official title: SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A, Charcot-Marie-Tooth Disease, Type 1B, Anti-MAG Neuropathy
- Being tested
- MD1003
- Keywords
- Neuropathy, Demyelinating polyradiculoneuropathy
- Medical subject headings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Peripheral Nervous System Diseases, Charcot-Marie-Tooth Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MD1003Drug
Also called High Dose Biotin
| Study group | Role | What they receive |
|---|---|---|
| MD1003 | Experimental | MD1003 100mg capsules, 1 capsule tid for 48 weeks Receives: Drug: MD1003 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor Nerve Conduction Velocity (m/Sec)
Absolute change from baseline at Week 48.
Measured: 48 weeks
Distal Latency (Msec)
Absolute change from baseline at Week 48.
Measured: 48 weeks
F Wave Latency (Msec)
Absolute change from baseline at Week 48.
Measured: 48 weeks
Length of Motor Nerve Potential
Absolute change from baseline at W48.
Measured: 48 weeks
Secondary outcomes (12)
ONLS (Overall Neuropathy Limitations Scale)
The ONLS focuses on upper and lower limb functions, and consists of a checklist for interviewing patients. It is scored from 0 to 5 on the upper limb section and from 0 to 7 on the lower limb section. A score of 0 indicates no limitations (the ceiling of the scale) and a score of 5 or 7 indicates no purposeful movement. Absolute change from baseline at week 48.
Measured: 48 weeks
Change From Baseline at Week 48 for Timed 10-meter Walk Test
Absolute change from baseline at week 48. The patient is instructed to walk at normal pace for 10 meters. Start and stop of performance time coincides with the toes of the leading foot crossing the 2-m mark and the 8-m mark, respectively. From these data, the speed may be calculated by dividing the middle 6 m by the time (in seconds).
Measured: 48 weeks
Absolute Change From Baseline at Week 48 for Medical Research Council (MRC) Subscore (Total Muscle) and Total Score
MRC score assessed in 19 muscles.
The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.
The patient's effort is graded on a scale of 0-5:
Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance.
Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side.
Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.
Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.
Grade 0: No movement is observed.
Measured: 48 weeks
INCAT Sensory Sum Score (ISS)
This sensory scale comprises pin prick and vibration sense plus a two point discrimination value in the arms and legs, and ranges from 0 ("normal sensation") to 20 ("most severe sensory deficit"). Absolute change from baseline at week 48.
Measured: 48 weeks
6-minute Walk Test
The 6MWT is a practical simple test that requires a 30 m (100-ft) hallway. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. Absolute change from baseline at week 48.
Measured: 48 weeks
Posturography Score
Computerized dynamic posturography (CDP) is a non-invasive specialized clinical assessment technique used to quantify the central nervous system adaptive mechanisms (sensory, motor and central) involved in the control of posture and balance, both in normal and abnormal conditions. Absolute change of speed in spontaneous speed condition from baseline at week 48.
Measured: 48 weeks
Excitability Testing: Supernormality (%)
Nerve excitability testing is a non-invasive approach in investigating the pathophysiology of peripheral nerve disorders, which determines the electrical properties of the nerve membrane at the site of stimulation. Absolute change from baseline at week 48.
After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). During the 10-30 ms following the end of the refractory period, the axon increases its excitability and the nerve fiber is more easily excited (the supernormal period). Depolarization of the node of Ranvier excites the adjacent internodes, which then charge with electric current as capacitors. Supernormality depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.
Measured: 48 weeks
Strength-duration Time Constant (ms)
This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.
Strength-duration Time Constant (ms) is a measurement of excitability, defined as the duration of the stimulus that has twice the strength of the rheobase current (see below). The lower the rheobase is, the higher is the Strenght duration time constant. Accordingly, higer values of SDTC are associated with better outcome.
Measured: 48 weeks
Rheobase (mA)
This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.
Rheobase is the minimal strength of an electrical stimulus of infinitely long duration that is able to cause excitation. Low values are associated with better outcome (the nerve becomes more excitable).
Measured: 48 weeks
Refractoriness (%)
This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline to week 48.
After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.
Measured: 48 weeks
Minimum Absolute Refractory Period (ms).
This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.
After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.
Measured: 48 weeks
Maximum Absolute Refractory Period (ms).
This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.
After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.
Measured: Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2016 (estimated)
- Study start5 Dec 2016
- Primary completion18 Mar 2019
- Study completion18 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Inflammatory Demyelinating PolyneuropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- MedDay Pharmaceuticals SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Alain CREANGE, MD, Principal investigator, Hôpital Henri Mondor, Créteil, FranceFrederic Sedel, MD, Study director, Medday Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02967679
- Sponsor's protocol ID
- MD1003CT2015-01 SERENDEM
- Status last verified
- Oct 2020
- First submitted
- 8 Nov 2016
- Last updated
- 2 Nov 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Creange A, Hutin E, Sedel F, Le Vigouroux L, Lefaucheur JP. High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study. BMC Neurol. 2023 Oct 30;23(1):389. doi: 10.1186/s12883-023-03440-y.
PubMed 37899433
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
- ClinicalTrials.gov ID
- NCT02967679
- Acronym / sponsor ID
- MD1003CT2015-01 SERENDEM
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A, Charcot-Marie-Tooth Disease, Type 1B, Anti-MAG Neuropathy
- Keywords
- Neuropathy, Demyelinating polyradiculoneuropathy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- MedDay Pharmaceuticals SAIndustry (pharma, biotech, devices)
- Study start
- 5 Dec 2016 (actual)
- Primary completion
- 18 Mar 2019 (actual)
- Study completion
- 18 Mar 2019 (actual)
- First posted
- 18 Nov 2016 (estimated)
- Results
- Posted 2 Nov 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MD1003 | Experimental | Drug: MD1003MD1003 100mg capsules, 1 capsule tid for 48 weeks |
Who may qualify
- Ages
- 20 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Male and female aged between 20 and 85 years.
- Patients fulfilling one of the following diagnosis:
- Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
- Five patients with proven genetic diagnosis of CMT1a or CMT1b
- Five patients with anti-MAG polyneuropathy.
Key exclusion criteria (11 listed)
- Any general chronic handicapping disease other than peripheral neuropathy
- Impossibility to perform the 10 meters walking test
- Impossibility to assess electrophysiological parameters
- Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer,
- Patients with hypersensitivity to MD1003 excipients (lactose)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MD1003Also: High Dose Biotin | Drug | MD1003 |
Primary outcome
Motor Nerve Conduction Velocity (m/Sec)
Time frame: 48 weeks
Absolute change from baseline at Week 48.
Distal Latency (Msec)
Time frame: 48 weeks
Absolute change from baseline at Week 48.
F Wave Latency (Msec)
Time frame: 48 weeks
Absolute change from baseline at Week 48.
Length of Motor Nerve Potential
Time frame: 48 weeks
Absolute change from baseline at W48.
12 secondary outcomes
ONLS (Overall Neuropathy Limitations Scale)
Time frame: 48 weeks
Change From Baseline at Week 48 for Timed 10-meter Walk Test
Time frame: 48 weeks
Absolute Change From Baseline at Week 48 for Medical Research Council (MRC) Subscore (Total Muscle) and Total Score
Time frame: 48 weeks
INCAT Sensory Sum Score (ISS)
Time frame: 48 weeks
6-minute Walk Test
Time frame: 48 weeks
Posturography Score
Time frame: 48 weeks
Excitability Testing: Supernormality (%)
Time frame: 48 weeks
Strength-duration Time Constant (ms)
Time frame: 48 weeks
Rheobase (mA)
Time frame: 48 weeks
Refractoriness (%)
Time frame: 48 weeks
Minimum Absolute Refractory Period (ms).
Time frame: 48 weeks
Maximum Absolute Refractory Period (ms).
Time frame: Week 48
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37899433Creange A, Hutin E, Sedel F, Le Vigouroux L, Lefaucheur JP. High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study. BMC Neurol. 2023 Oct 30;23(1):389. doi: 10.1186/s12883-023-03440-y.
Related trials for Chronic Inflammatory Demyelinating Polyneuropathy
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
RecruitingObservational study
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Charcot-Marie-Tooth, CMT1A
Recruiting
High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project
Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Neuropathy
Active, not recruitingPhase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alain CREANGE, MD principal investigator
Hôpital Henri Mondor, Créteil, France
Frederic Sedel, MD study director
Medday Pharmaceuticals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MD1003 in people with Chronic Inflammatory Demyelinating Polyneuropathy and Peripheral Neuropathy, run by MedDay Pharmaceuticals SA at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Nov 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor Nerve Conduction Velocity (m/Sec) (time frame: 48 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02967679, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2020.